Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: cross-over designed study.
OBJECTIVES: The purpose of the present study was to determine changes of biochemical risk factors of thromboembolism especially of TFPI during the use of oral versus transdermal administration of early estrogen replacement therapy.
METHODS: In a 12-week prospective, randomized, cross-over trial, oestradiol was ad.....